Cyclin-Dependent Kinase 5/p35/p39: A Novel and Imminent Therapeutic Target for Diabetes Mellitus

Table 1

IC₅₀ (nM/μM) of various CDK5 inhibitors.

Compound no.	Compound	Chemical name	IC50 CDK5/p25
1		2-[[9-Methyl-6-[(phenylmethyl)amino]-9H-purin-2-yl]amino]-ethanol	3 μM
2		2-(6-Benzylamino)-9-isopropyl-9H-purin-2-ylamino)butane-1-ol	0.2 μM
3		N-(5-(6,7-Diphenyl-5H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazin-3-yl)-4-methylthiophen-2-yl)acetamide	44 ± 2 nM
4		2,2-Dichloro-N-(5-(6,7-Diphenyl-5H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazin-3-yl)-4-methylthiophen-2-yl) acetamide	72 ± 2 nM
5		N-(4-Methyl-5-(6-phenyl-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazol-3-yl)thiophen-2-yl)acetamide	42 ± 1 nM
6		2,2-Dichloro-N-(4-methyl-5-(6-phenyl-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazol-3-yl)thiophen-2-yl)acetamide	30 ± 1 nM
7		2-(4-(Benzylamino)-1-isopropyl-1H-benzo[d]imidazol-6-yloxy)butan-1-ol	13 μM
8		N-(3-((2-Acetamidothiazol-4-yl)methyl)-5-(2-(2-benzylidenehydrazinyl)-2-oxoethylthio)-4H-1,2,4-triazol-4-yl)benzamide	048 ± 02 nM
9		1-((1H-Imidazol-5-yl)methyl)-7-fluoro-9H-pyrido[3,4-𝑏]indole	05 μM
10			34 ± 1 nM